World's first ovarian cancer vax developed in the UK gets more funding; Here's what we know about it

Scientists at the University of Oxford are developing a new vaccine called OvarianVax, aimed at preventing ovarian cancer. Cancer Research UK, which funds the study, has termed it as an “exciting step forward.” Ovarian cancer impacts the ovaries, with around 7,500 new cases diagnosed each year in the UK, and approximately 4,100 women die from the disease annually.

Treatment methods for ovarian cancer generally include surgery and chemotherapy, with additional options like targeted medicines and hormone treatments available based on the type and spread of the cancer.

OvarianVax is being designed to help the immune system recognize and attack the earliest stages of ovarian cancer, potentially preventing the development of the disease. However, it is expected to be many years before the vaccine becomes widely available. Currently, scientists are working on identifying cellular targets for the vaccine and determining which proteins on ovarian cancer cells are most effectively recognized by the immune system. This research will be followed by clinical trials to test the vaccine’s effectiveness and safety.


Professor Ahmed Ahmed, director of the ovarian cancer cell laboratory at MRC Weatherall Institute of Molecular Medicine at the University of Oxford, explained the goal of the vaccine, stating, “I am optimistic because we are talking about preventing the very first few cancer cells that develop – and not trying to cure or treat or prevent the tumour coming back.”

Vaccines as a method to combat cancer are relatively new, with ongoing trials exploring their effectiveness against cancers such as melanoma, pancreatic, and lung cancer. Scientists are working towards creating the world's first vaccine for ovarian cancer.